Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UP-SPOUT: upadacitinib versus placebo for axial outcomes in active psoriatic arthritis
2023-510242-24-00Phase 4Authorised
- Sponsor
- CARE Arthritis
- Start
- Jun 2025
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 4, randomised, double-blind trial in psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) comparing Upadacitinib with Placebo (2 arms). Primary endpoint: Change from baseline in total SPARCC MRI inflammation score at Week 12 in the DMARD inadequate responder subgroup. Planned start Jun 2025; status: authorised.
02
Drugs
upadacitinib
03
Conditions
psoriatic arthritis (PsA)axial spondyloarthritis (axSpA)
Beyond the preview
Go deeper on 2023-510242-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510242-24-00.